These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 1789901)
41. In vitro susceptibility of Haemophilus influenzae to cefaclor, cefixime, cefetamet and loracarbef. Williams JD; Powell M; Fah YS; Seymour A; Yuan M Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):748-51. PubMed ID: 1425737 [TBL] [Abstract][Full Text] [Related]
42. Activity of FCE 22891 compared with cefuroxime axetil and cefixime in pulmonary and subcutaneous infections in mice. Rossi R; Castellani P; Younes G; Della Bruna C J Antimicrob Chemother; 1989 Mar; 23 Suppl C():149-55. PubMed ID: 2732136 [TBL] [Abstract][Full Text] [Related]
43. Antimicrobial activity and spectrum of ceftibuten (7432-S, SCH 39720)--a review of United States and Canadian results. Jones RN Diagn Microbiol Infect Dis; 1991; 14(1):37-43. PubMed ID: 2013209 [TBL] [Abstract][Full Text] [Related]
44. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten. Schatz BS; Karavokiros KT; Taeubel MA; Itokazu GS Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562 [TBL] [Abstract][Full Text] [Related]
45. Third generation oral cephalosporins: comparative in vitro kinetics. Speciale A; Blandino G; Nicoletti G J Chemother; 1995 May; 7 Suppl 1():9-12. PubMed ID: 8618112 [TBL] [Abstract][Full Text] [Related]
46. Comparative in vitro activity of cefetamet (RO 15-8074). Machka K; Braveny I Eur J Clin Microbiol; 1987 Aug; 6(4):496-7. PubMed ID: 3478193 [No Abstract] [Full Text] [Related]
47. Comparative in-vitro activity of cefdinir against multiresistant Haemophilus influenzae. Perea EJ; Garcia Iglesias MC J Antimicrob Chemother; 1994 Jul; 34(1):161-4. PubMed ID: 7961203 [No Abstract] [Full Text] [Related]
48. Repeated exposition to subinhibitory concentrations of antibiotic in vitro readily decreases susceptibility of Neisseria gonorrhoeae to rifampicin, but not to new cephalosporins and penicillin G. Korting HC; Behrendt H; Roth KH; Neubert U Chemotherapy; 1984; 30(6):366-72. PubMed ID: 6097409 [TBL] [Abstract][Full Text] [Related]
49. [The antibacterial activity of new cephem antibiotics against clinical isolates. A comparison of the antibacterial activity of cefotaxime with 6 other antibiotics]. Miwatani T; Takeda Y; Kotera K; Nishimura T; Takashima T; Hiromatsu K; Tabuki K; Fujimoto S; Kamiki T; Yoshizaki E; Yabuuchi E; Shimizu Y; Matsunaga K; Yamanaka K; Furuta I; Iimori M; Kodama J; Tanaka M; Maejima K; Nukina M; Takashima E; Takahashi M; Harikane O; Masutani T Jpn J Antibiot; 1983 Feb; 36(2):260-76. PubMed ID: 6304368 [TBL] [Abstract][Full Text] [Related]
50. The effect of N-formimidoyl thienamycin, ceftazidime, cefotiam, ceftriaxone and cefotaxime on non-fermentative Gram-negative rods, Aeromonas, Plesiomonas and Enterobacter agglomerans. von Graevenitz A; Bucher C Infection; 1982; 10(5):293-8. PubMed ID: 6293976 [TBL] [Abstract][Full Text] [Related]
51. [Analysis of susceptibility of bacteria isolated from clinical material to cefuroxime, ceftazidime and cefotaxime]. Giedrys-Kalemba S; Bilska I Med Dosw Mikrobiol; 1993; 45(2):173-6. PubMed ID: 8309292 [TBL] [Abstract][Full Text] [Related]
52. [In vitro antibacterial activity of cefodizime (HR 221) on 323 hospital strains of Gram negative bacilli. Comparison with cefotiam, cefoperazone, cefotetan and cefotaxime]. Le Noc P; Bryskier A; Le Noc D Pathol Biol (Paris); 1985 May; 33(5):399-403. PubMed ID: 3897972 [TBL] [Abstract][Full Text] [Related]
53. [Pharmacokinetics of cefixime in volunteers and a literature comparison with the new ester prodrug cephalosporins]. Kees F; Naber KG Infection; 1990; 18 Suppl 3():S150-4. PubMed ID: 2079377 [TBL] [Abstract][Full Text] [Related]
54. Comparison of cefpodoxime proxetil and cefixime in the treatment of acute otitis media in infants and children. Otitis Study Group. Asmar BI; Dajani AS; Del Beccaro MA; Mendelman PM Pediatrics; 1994 Dec; 94(6 Pt 1):847-52. PubMed ID: 7971000 [TBL] [Abstract][Full Text] [Related]
55. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Perry CM; Brogden RN Drugs; 1996 Jul; 52(1):125-58. PubMed ID: 8799689 [TBL] [Abstract][Full Text] [Related]
56. Cefpodoxime 10 μg disc screening test for detection of Neisseria gonorrhoeae with mosaic PBP2 and decreased susceptibility to extended-spectrum cephalosporins for public health purposes. Limnios A; Tapsall J; Kahlmeter J; Hogan T; Ray S; Lam A; Unemo M APMIS; 2011 Jun; 119(6):356-63. PubMed ID: 21569093 [TBL] [Abstract][Full Text] [Related]
57. [Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins]. Bauernfeind A; Jungwirth R; Schweighart S; Theopold M Infection; 1990; 18 Suppl 3():S155-67. PubMed ID: 2079378 [TBL] [Abstract][Full Text] [Related]
58. Synergism and antagonism of ceftizoxime and other new cephalosporins. Moellering RC; Willey S; Eliopoulos GM J Antimicrob Chemother; 1982 Nov; 10 Suppl C():69-79. PubMed ID: 6296032 [No Abstract] [Full Text] [Related]
59. In vitro antimicrobial activity of ceftizoxime. Schell RF; LeFrock JL; Smith BR; Francisco M Chemotherapy; 1983; 29(6):408-14. PubMed ID: 6317295 [TBL] [Abstract][Full Text] [Related]
60. [Activity of new cephalosporins against polyresistant bacterial strains]. De Toffoli A; Fantin B Minerva Med; 1983 Mar; 74(9-10):427-31. PubMed ID: 6300736 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]